AKSO HEALTH GROUP AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Expressed in U.S. dollars, except for shares) As of September 30, As of March 31, Note 2025 2025 ASSETS CURRENT ASSETS Cash and cash equ

AKSO HEALTH GROUP AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Expressed in U.S. dollars, except for shares)

See notes to the unaudited condensed consolidated

financial statements

AKSO HEALTH GROUP AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS

OF OPERATIONS AND COMPREHENSIVE (LOSS)

(Expressed in U.S. dollars, except for shares)

See notes to the unaudited condensed consolidated

financial statements

AKSO HEALTH GROUP AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS

OF CHANGES IN SHAREHOLDERS' EQUITY

(Expressed in U.S. dollars, except share data)

See notes to the unaudited condensed consolidated

financial statements

AKSO HEALTH GROUP AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS

(Expressed in U.S. dollars, except share data)

See notes to the unaudited condensed consolidated

financial statements

AKSO HEALTH GROUP AND SUBSIDIARIES

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

Note 1 - BUSINESS DESCRIPTION

Organization and description of business

Akso Health Group, formerly known as Xiaobai Maimai

Inc., is a limited company incorporated under the laws of the Cayman Islands on April 25, 2016. Akso Health Group ("Akso Health"

or the "Company"), its subsidiaries, and consolidated variable interest entities ("VIEs") (collectively the "Company"),

previously operated an online Peer to Peer ("P2P") marketplace business and micro-lending business in the People's Republic

of China (the "PRC"). Since May 2019, the Company has ceased to issue new loans through its micro-lending business and since

October 2019, the Company has ceased to conduct its P2P business. On December 30, 2020, the Company completed the disposition transaction

of its P2P business.

In May 2020, the Company launched its social

e-commerce platform to offer high-quality and affordable branded products through collaboration with online and offline merchants.

In addition, the Company is in the process of developing a new business as a cancer therapy and radiotherapy oncology service

provider with operations in the U.S. The Company plans to open 2 vaccine research centers and 100 radiation oncology centers to be

located on the east coast serving cancer patients in need of varying stages of treatment, including specialized radiation therapy

centers for radiotherapy (RT), personalized consultation, conventional treatment planning, and other cancer related treatment

services. On December 3, 2021, the shareholders approved the Company's plan to change its name to "Akso Health

Group". In January 2022, three centers were established in US and the Company started its business of sales of medical devices

in US market. In April 2022, the Company started its sales of medical devices in China market through its subsidiary Qingdao Akso

Health Management Co., Ltd. In May 2023, the Company disposed its social E-commerce business and would focus on healthcare business

in the future. On April 15, 2024, the Company, through its wholly owned subsidiary Tianjin Akso Enterprise Management Co., Ltd.

acquired 50% equity interests in Tianjin Wangyi Cloud Technology Co., Ltd, and exploring its business in the field of clinic

and Internet hospital, and in June and December 2024, the Company acquired the remaining 50% equity interests of Tianjin Wangyi

Cloud Technology Co., Ltd. from minority shareholders, the acquisition closed on December 10, 2024. Since April 2024, the Company

also started its provision of marketing promotion service business in the field of car insurance industry.

As of September 30, 2025, the Company's principal subsidiaries

NOTE 2 - GOING CONCERN

The accompanying unaudited condensed consolidated

financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization

of assets and satisfaction of liabilities in the normal course of business. As indicated therein, the Company had cash and cash equivalents

of approximately $11.1 million as of September 30, 2025. The net loss of approximately $1.3 million and the net cash used in investing

activities of US$166.4 million for the six months then ended are primarily attributable to the Company's deliberate and significant

strategic investment in building its Internet Hospital business platform, a key initiative for its long-term growth. The accumulated deficit

reflects the Company's investment phase in these strategic areas.

Management believes that the Company's capital

resources are currently sufficient to maintain its business operations and meet its working capital requirements for at least the next

twelve months. This belief is based on an evaluation of its available cash balance, projected operational needs, and the committed financial

support available from its controlling shareholder.

The unaudited condensed consolidated financial statements

do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Note 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited condensed consolidated

financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US

GAAP") and have been consistently applied. Certain prior year balances in the unaudited condensed consolidated statements of operations

and comprehensive (loss) and cash flows have been reclassified to the current year's presentation.

Basis of consolidation

The accompanying unaudited condensed consolidated

financial statements include the financial statements of the Company, and entities controlled by the Company and its subsidiaries for

which the Company is the primary beneficiary.

A subsidiary is an entity in which the Company,

directly or indirectly, controls more than one half of the voting powers; or has the power to appoint or remove the majority of the members

of the board of directors; or to cast a majority of votes at the meeting of directors; or has the power to govern the financial and operating

policies of the investee under a statute or agreement among the shareholders or equity holders.

All intercompany transactions and balances among

the Company and its subsidiaries have been eliminated upon consolidation.

The preparation of unaudited condensed consolidated

financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts

of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported

amounts of revenue and expenses during each reporting period. Actual results could differ from such estimates. Significant accounting

estimates reflected in the Company's unaudited condensed consolidated financial statements include estimates and judgments applied

in allocation of revenue with various performance obligations, allowance for accounts receivable, impairment on long-term investments,

impairment on intangible assets, valuation allowance for deferred tax assets and allowance for loans receivable and other receivable.

Fair value of financial instruments

Fair value is the price that would be received

from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When

determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers

the principal or most advantageous market in which it would transact and the market-based risk measurement or assumptions that market

participants would use when pricing the asset or liability.

The Company follows the provisions of Financial

Accounting Standards Board ("FASB"), Accounting Standards Codification ("ASC") 820, Fair Value Measurements and